J-147
10 mg
| 99.61%
TargetMol
J-147 is an experimental drug with reported effects against both Alzheimer’s disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.
More Information
Supplier Page
J-147
25 mg
| 99.61%
TargetMol
J-147 is an experimental drug with reported effects against both Alzheimer’s disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.
More Information
Supplier Page
J-147
50 mg
| 99.61%
TargetMol
J-147 is an experimental drug with reported effects against both Alzheimer’s disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.
More Information
Supplier Page
J-147
5 mg
| 99.61%
TargetMol
J-147 is an experimental drug with reported effects against both Alzheimer’s disease and ageing in mouse models of accelerated aging. It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in the pathogenesis of diabetic neuropathy.
More Information
Supplier Page
ISX-9
100 mg
| 98.26%
TargetMol
ISX-9
10 mg
| 98.26%
TargetMol
ISX-9
50 mg
| 98.26%
TargetMol
ISX-9
5 mg
| 98.26%
TargetMol
AT-56
5 mg
| 98.43%
TargetMol
AT56, a specific inhibitor of prostaglandin D2 synthase enzymatic activity, blunted adipogenic aldosterone effects.
More Information
Supplier Page
AT-56
50 mg
| 98.43%
TargetMol
AT56, a specific inhibitor of prostaglandin D2 synthase enzymatic activity, blunted adipogenic aldosterone effects.
More Information
Supplier Page